Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients

Elana Shaw; William M. Wuest

doi:10.1039/c9md00566h

Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients

RSC Medicinal Chemistry ◽

10.1039/c9md00566h ◽

2020 ◽

Vol 11 (3) ◽

pp. 358-369 ◽

Cited By ~ 3

Author(s):

Elana Shaw ◽

William M. Wuest

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Combination Therapy

Virulence attenuating combination therapy may be a promising approach to treating chronic P. aeruginosa infections in patients with cystic fibrosis.

Download Full-text

Monotherapy versus Combination Therapy for the Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients

JOURNAL OF ANTIBIOTICS RESEARCH ◽

10.15744/2574-5980.2.105 ◽

2018 ◽

Vol 2 (1) ◽

Author(s):

Alkhoury R ◽

Kinkar E ◽

Nokhbeh R ◽

Saleh MT

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Combination Therapy

Download Full-text

2395. Mechanism-Based-Susceptibility Testing (MBST) Using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-Pa?

Open Forum Infectious Diseases ◽

10.1093/ofid/ofy210.2048 ◽

2018 ◽

Vol 5 (suppl_1) ◽

pp. S714-S714

Author(s):

Lilian M Abbo ◽

Mohamad Yasmin ◽

Steven H Marshall ◽

Federico Perez ◽

Mónica Corzo-Pedrosa ◽

...

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Combination Therapy ◽

Transplant Recipient ◽

Lung Transplant ◽

Susceptibility Testing ◽

Lung Transplant Recipient ◽

Drug Resistant ◽

Disc Diffusion ◽

Extensively Drug Resistant

Download Full-text

Pseudomonas aeruginosa acquisition in cystic fibrosis: a role for surfactant protein D and mannose-binding lectin?

Klinische Pädiatrie ◽

10.1055/s-0030-1261563 ◽

2010 ◽

Vol 222 (S 01) ◽

Author(s):

E Tutdibi ◽

A Schwarz ◽

D Monz ◽

G Dockter ◽

L Gortner

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Surfactant Protein ◽

Mannose Binding Lectin ◽

Surfactant Protein D ◽

Mannose Binding ◽

Binding Lectin

Download Full-text

A Phase 3 Study Design of Pulmaquin® in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas aeruginosa (PA)

Pneumologie ◽

10.1055/s-0036-1592235 ◽

2016 ◽

Vol 70 (10) ◽

Cited By ~ 1

Author(s):

A O'Donnell ◽

D Bilton ◽

D Serisier ◽

A Wanner ◽

J Froehlich ◽

...

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Study Design ◽

Phase 3

Download Full-text

Anti-Pseudomonas aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis

Pneumologie ◽

10.1055/s-0036-1592252 ◽

2016 ◽

Vol 70 (10) ◽

Author(s):

G Suarez-Cuartin ◽

O Sibila ◽

A Smith ◽

H Abo-Leyah ◽

A Rodrigo-Troyano ◽

...

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Igg Antibodies ◽

Airway Infection ◽

Chronic Airway

Download Full-text

Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis

Case Medical Research ◽

10.31525/cmr-de5510 ◽

2019 ◽

Author(s):

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Lung Infection ◽

Orphan Designation ◽

Amikacin Sulfate

Download Full-text

Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center.

Case Medical Research ◽

10.31525/ct1-nct03910920 ◽

2019 ◽

Author(s):

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa

Download Full-text

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

Case Medical Research ◽

10.31525/ct1-nct04038710 ◽

2019 ◽

Author(s):

Keyword(s):

Cystic Fibrosis ◽

Combination Therapy ◽

Clinical Outcomes ◽

Triple Combination ◽

Triple Combination Therapy

Download Full-text

Faculty Opinions recommendation of Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1065903.518850 ◽

2007 ◽

Author(s):

Joanna Goldberg

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Interleukin 1 ◽

Lung Infection ◽

Transmembrane Conductance Regulator ◽

Transmembrane Conductance ◽

Cystic Fibrosis Transmembrane ◽

Chronic Lung Infection

Download Full-text

Faculty Opinions recommendation of A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1089099.542264 ◽

2007 ◽

Author(s):

Rino Rappuoli

Keyword(s):

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study

Download Full-text